Compare EAD & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EAD | IVVD |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.7M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | EAD | IVVD |
|---|---|---|
| Price | $6.66 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 205.8K | ★ 3.4M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $6.24 | $0.49 |
| 52 Week High | $7.18 | $3.07 |
| Indicator | EAD | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 55.92 |
| Support Level | $6.52 | $1.41 |
| Resistance Level | $6.91 | $1.77 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 94.32 | 83.33 |
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.